Amplification of thymosin beta 10 and AKAP13 genes in metastatic and aggressive papillary thyroid carcinomas

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 449-458

  Fehér, Liliána Z ^a   Pocsay, Gábor ^b   Krenács, László ^c   Zvara, Ágnes ^a   Bagdi, Eniko ^c   Pocsay, Réka ^b   Lukács, Géza ^d   Gyory, Ferenc ^d   Gazdag, Andrea ^b   Tarkó, Erzsébet ^e   Puskás, László G ^a  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

^b Pandy Kalman County Hospital   (Hungary)

^c Laboratory of Tumour Pathology and Molecular Diagnostics   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

^e Borsod County Teaching Hospital   (Hungary)

Author keywords

AKAP13; Genomic amplification; Metastasis; Papillary thyroid carcinoma (PTC); Thymosin beta 10 (TB10); Tre 2 oncogene

Indexed keywords

A KINASE ANCHOR PROTEIN 13 GENE; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RECURRENCE; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; EUKARYOTIC INITIATION FACTOR 4E BINDING PROTEIN 3 GENE; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENE LOCUS; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MALE; METASTASIS POTENTIAL; NUCLEOTIDE SEQUENCE; ONCOGENE; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; THYMOSIN BETA 10 GENE; THYROID PAPILLARY CARCINOMA; TRAFFICKING PROTEIN KINESIN BINDING 2 GENE; TRE 2 GENE;

A KINASE ANCHOR PROTEINS; ADOLESCENT; ADULT; AGED; BONE NEOPLASMS; CARCINOMA, PAPILLARY; COMPARATIVE GENOMIC HYBRIDIZATION; DNA, NEOPLASM; FEMALE; FOLLOW-UP STUDIES; GENE AMPLIFICATION; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; REAL-TIME POLYMERASE CHAIN REACTION; RISK FACTORS; THYMOSIN; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84863429385     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9467-7     Document Type: Article

References (65)

1. Hundahl SA, Fleming ID, Fremgen AM et al (1998) A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2646
2. Samaan NA, Schultz PN, Hickey RC et al (1992) The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. J Clin Endocrinol Metab 75:714-720
3. Mazzaferri EL, Jhiang SM (1994) Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 97:418-428
4. Gilliland FD, Hunt WC, Morris DM et al (1997) Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer 79:564-573
5. Sherman SI, Brierley JD, Sperling M et al (1998) Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. Cancer 83:1012-1021
6. Tsang RW, Brierley JD, Simpson WJ et al (1998) The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82:375-388
7. Nikiforova MN, Kimura ET, Gandhi M et al (2003) BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 88:5399-5404
8. Fagin JA (2004) Challenging dogma in thyroid cancer molecular genetics-role of RET/PTC and BRAF in tumour initiation. J Clin Endocrinol Metab 89:4264-4266
9. Xing M (2005) BRAF mutation in thyroid cancer. Endocr Relat Cancer 12:245-262
10. Xing M, Westra WH, Tufano RP et al (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90:6373-6379
11. Kondo T, Ezzat S, Asa SL (2006) Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat Rev Cancer 6:292-306
12. Adeniran AJ, Zhu Z, Gandhi M et al (2006) Correlation between genetic alterations and microscopic features, clinical manifestations, and prognostic characteristics of thyroid papillary carcinomas. Am J Surg Pathol 30:216-222
13. Giannini R, Ugolini C, Lupi C et al (2007) The heterogeneous distribution of BRAF mutation supports the independent clonal origin of distinct tumour foci in multifocal papillary thyroid carcinoma. J Clin Endocrinol Metab 92:3511-3516
14. Ciampi R, Nikiforov YE (2007) RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 148:936-941
15. Suarez HG (1998) Genetic alterations in human epithelial thyroid tumours. Clin Endocrinol (Oxf) 8:531-546
16. Garcia-Rostan G, Zhao H, Camp RL et al (2003) Ras mutations are associated with aggressive tumour phenotypes and poor prognosis in thyroid cancer. J Clin Oncol 1:3226-3235
17. Ciampi R, Knauf JA, Kerler R et al (2005) Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer. J Clin Invest 115:94-101
18. Santoro M, Papotti M, Chiappetta G et al (2002) RET activation and clinicopathologic features in poorly differentiated thyroid tumours. J Clin Endocrinol Metab 87:370-379
19. Tallini G, Santoro M, Helie M et al (1998) RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumour phenotypes. Clin Cancer Res 4:287-294
20. Nikiforov YE (2002) RET/PTC rearrangement in thyroid tumors. Endocr Pathol 13:3-16
21. Greco A, Miranda C, Pagliardini S et al (1997) Chromosome 1 rearrangements involving the genes TPR and NTRK1 produce structurally different thyroid-specific TRK oncogenes. Genes Chromosomes Cancer 19:112-123
22. Beimfohr C, Klugbauer S, Demidchik EP et al (1999) NTRK1 rearrangement in papillary thyroid carcinomas of children after the Chernobyl reactor accident. Int J Cancer 80:842-847
23. Ito T, Seyama T, Mizuno T et al (1992) Unique association of p53 mutations with undifferentiated but not with differentiated carcinomas of the thyroid gland. Cancer Res 52:1369-1371
24. Fagin JA, Matsuo K, Karmakar A et al (1993) High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest 91:179-184
25. Asakawa H, Kobayashi T (2002) Multistep carcinogenesis in anaplastic thyroid carcinoma: a case report. Pathology 34:94-97
26. Garcia-Rostan G, Camp RL, Herrero A et al (2001) Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis. Am J Pathol 158:987-996
27. Huang Y, Prasad M, Lemon WJ et al (2001) Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 98:15044-15049
28. Puskas LG, Juhasz F, Zarva A et al (2005) Gene profiling identifies genes specific for well-differentiated epithelial thyroid tumors. Cell Mol Biol (Noisy-le-grand) 51:177-186
29. Puskas LG, Farid NR (2004) Gene expression in thyroid tumors. Cancer Treat Res 122:265-271
30. Gunn SR, Robetorye RS, Mohammed MS et al (2007) Comparative genomic hybridization arrays in clinical pathology: progress and challenges. Mol Diagn Ther 11:73-77
31. Hemmer S, Wasenius VM, Knuutila S et al (1999) DNA copy number changes in thyroid carcinoma. Am J Pathol 154:1539-1547
32. Kjellman P, Lagercrantz S, Hoog A et al (2001) Gain of 1q and loss of 9q21.3-q32 are associated with a less favorable prognosis in papillary thyroid carcinoma. Genes Chromosomes Cancer 32:43-49
33. Rodrigues R, Roque L, Espadinha C et al (2007) Comparative genomic hybridization, BRAF, RAS, RET, and oligo-array analysis in aneuploid papillary thyroid carcinomas. Oncol Rep 18:917-926
34. Lee JJ, Au AY, Foukakis T et al (2008) Array-CGH identifies cyclin D1 and UBCH10 amplicons in anaplastic thyroid carcinoma. Endocr Relat Cancer 15:801-815
35. Finn S, Smyth P, O'Regan E et al (2007) Low-level genomic instability is a feature of papillary thyroid carcinoma: an array comparative genomic hybridization study of laser capture microdissected papillary thyroid carcinoma tumors and clonal cell lines. Arch Pathol Lab Med 131:65-73
36. Wreesmann VB, Sieczka EM, Socci ND et al (2004) Genomewide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64:3780-3789
37. Unger K, Malisch E, Thomas G et al (2008) Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC. Oncogene 27:4592-4602
38. Kitamura Y, Shimizu K, Tanaka S et al (2000) Association of allelic loss on 1q, 4p, 7q, 9p, 9q, and 16q with postoperative death in papillary thyroid carcinoma. Clin Cancer Res 6:1819-1825
39. Pacini F, Schlumberger M, Harmer C et al (2005) Post-surgical use of radioiodine 131I in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 153:651-659
40. Pacini F, Schlumberger M, Dralle G et al (2006) European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 154:767-803
41. Feher LZ, Balazs M, Kelemen JZ et al (2006) Improved DOPPCR-based representational whole-genome amplification using quantitative real-time PCR. Diagn Mol Pathol 15:43-48
42. Telenius H, Carter NP, Bebb CE et al (1992) Degenerate oligonucleotide-primed PCR: general amplification of target DNA by a single degenerate primer. Genomics 13:718-725
43. Nagy J, Feher LZ, Sonkodi I et al (2005) A second field metachronous Merkel cell carcinoma of the lip and the palatine tonsil confirmed by microarray-based comparative genomic hybridisation. Virchows Arch 446:278-286
44. Yang YH, Dudoit S, Luu P et al (2002) Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. Nucleic Acids Res 30:e15
45. Pfaffl MW (2001) A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 29:e45
46. Onno M, Nakamura T, Mariage-Samson R et al (1993) Human TRE17 oncogene is generated from a family of homologous polymorphic sequences by single-base changes. DNA Cell Biol 12:107-118
47. Martinu L, Masuda-Robens JM, Robertson SE et al (2004) The TBC (Tre-2/Bub2/Cdc16) domain protein TRE17 regulates plasma membrane-endosomal trafficking through activation of Arf6. Mol Cell Biol 24:9752-9762
48. Masuda-Robens JM, Kutney SN, Qi H et al (2003) The TRE17 oncogene encodes a component of a novel effector pathway for Rho GTPases Cdc42 and Rac1 and stimulates actin remodeling. Mol Cell Biol 23:2151-2161
49. Smith MJ, Pozo K, Brickley K et al (2006) Mapping the GRIF-1 binding domain of the kinesin, KIF5C, substantiates a role for GRIF-1 as an adaptor protein in the anterograde trafficking of cargoes. J Biol Chem 281:27216-27228
50. Brickley K, Smith MJ, Beck M et al (2005) GRIF-1 and OIP106, members of a novel gene family of coiled-coil domain proteins: association in vivo and in vitro with kinesin. J Biol Chem 280:14723-14732
51. Yasuhara T, Okamoto A, Kitagawa T et al (2005) FGF7-like gene is associated with pericentric inversion of chromosome 9, and FGF7 is involved in the development of ovarian cancer. Int J Oncol 26:1209-1216
52. Hishikawa Y, Tamaru N, Ejima K et al (2004) Expression of keratinocyte growth factor and its receptor in human breast cancer: its inhibitory role in the induction of apoptosis possibly through the overexpression of Bcl-2. Arch Histol Cytol 67:455-464
53. Firth JD, Putnins EE (2004) Keratinocyte growth factor 1 inhibits wound edge epithelial cell apoptosis in vitro. J Invest Dermatol 122:222-231
54. Diviani D, Abuin L, Cotecchia S et al (2004) Anchoring of both PKA and 14-3-3 inhibits the Rho-GEF activity of the AKAP-Lbc signaling complex. EMBO J 23:2811-2820
55. Shibolet O, Giallourakis C, Rosenberg I et al (2007) AKAP13, a RhoA GTPase-specific guanine exchange factor, is a novel regulator of TLR2 signaling. J Biol Chem 282:35308-35317
56. Wirtenberger M, Tchatchou S, Hemminki K et al (2006) Association of genetic variants in the Rho guanine nucleotide exchange factor AKAP13 with familial breast cancer. Carcinogenesis 27:593-598
57. Chiappetta G, Pentimalli F, Monaco M et al (2004) Thymosin beta-10 gene expression as a possible tool in diagnosis of thyroid neoplasias. Oncol Rep 12:239-243
58. Takano T, Hasegawa Y, Miyauchi A et al (2002) Quantitative analysis of thymosin beta-10 messenger RNA in thyroid carcinomas. Jpn J Clin Oncol 32:22
59. Hall AK (1995) Thymosin beta-10 accelerates apoptosis. Cell Mol Biol Res 41:167-180
60. Maelan AE, Rasmussen TK, Larsson LI (2007) Localization of thymosin beta10 in breast cancer cells: relationship to actin cytoskeletal remodeling and cell motility. Histochem Cell Biol 127:109-113
61. Califano D, Monaco C, Santelli G et al (1998) Thymosin beta-10 gene overexpression correlated with the highly malignant neoplastic phenotype of transformed thyroid cells in vivo and in vitro. Cancer Res 58:823-828
62. Santelli G, Califano D, Chiappetta G et al (1999) Thymosin beta-10 gene overexpression is a general event in human carcinogenesis. Am J Pathol 155:799-804
63. Lee SH, Son MJ, Oh SH et al (2005) Thymosin {beta}(10) inhibits angiogenesis and tumour growth by interfering with Ras function. Cancer Res 65:137-148
64. Santelli G, Bartoli PC, Giuliano A et al (2002) Thymosin beta-10 protein synthesis suppression reduces the growth of human thyroid carcinoma cells in semisolid medium. Thyroid 12:765-772
65. Huff T, Muller CS, Otto AM et al (2001) beta-Thymosins, small acidic peptides with multiple functions. Int J Biochem Cell Biol 33:205-220